Modelli di dati selezionati

Devi effettuare il log in per selezionare i modelli di dati da scaricare per successive analisi

28 Risultati di ricerca.
rilevanza Valutazione Più recente Meno recente

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Rheumatic Diseases; Systemic Lupus Erythematosus or Cutaneous Lupus; Sjogren's Syndrome (Report Final and Annex Report 2 Final)

- 02/11/20 - 1 modulo, 25 itemgroups, 95 elementi, 1 linguaggio
Itemgroups: Administrative, Rheumatic Diseases, Rheumatic Diseases - Signs and Symptoms, Rheumatic diseases - Other signs and symptoms, Rheumatic diseases - Other signs and symptoms , Rheumatic diseases - Diagnostic Test Results, Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other Diagnostic Test Results , Rheumatic diseases - Other diagnostic Procedure, Systemic Lupus Erythematosus or Cutaneous Lupus, Systemic Lupus Erythematosus or Cutaneous Lupus - Signs and symptoms (supporting the final diagnosis), Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Signs and symptoms , Systemic Lupus Erythematosus or Cutaneous Lupus - Diagnostic Test Results, Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other Diagnostic Test Results , Systemic Lupus Erythematosus or Cutaneous Lupus - Other diagnostic Procedure , Sjogren's Syndrome, Sjogren's Syndrome - Signs and symptoms (supporting the final diagnosis), Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Other Signs and symptoms , Sjogren's Syndrome - Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other Diagnostic Test Results , Sjogren's Syndrome - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check

- 17/09/21 - 1 modulo, 4 itemgroups, 29 elementi, 1 linguaggio
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Eligibility Check (Annex Report 2 Final)

- 17/09/21 - 1 modulo, 4 itemgroups, 29 elementi, 1 linguaggio
Itemgroups: Administrative, Eligibility Check, Inclusion Criteria, Exclusion Criteria
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Autoimmune Liver Diseases; Sarcoidosis; Other diseases (Report Final and Annex Report 2 Final)

- 03/11/20 - 1 modulo, 23 itemgroups, 85 elementi, 1 linguaggio
Itemgroups: Administrative, Autoimmune Liver Diseases, Autoimmune Liver Diseases - Signs and Symptoms, Autoimmune Liver Diseases - Other signs and symptoms, Autoimmune Liver Diseases - Other signs and symptoms , Autoimmune Liver Diseases - Diagnostic Test Results, Autoimmune Liver Diseases - Other Diagnostic Test Results , Autoimmune Liver Diseases - Other Diagnostic Test Results , Autoimmune Liver Diseases - Other diagnostic Procedure, Sarcoidosis, Sarcoidosis - Signs and symptoms, Sarcoidosis - Other Signs and symptoms, Sarcoidosis - Other Signs and symptoms , Sarcoidosis - Diagnostic Test Results, Sarcoidosis - Other Diagnostic Test Results , Sarcoidosis - Other Diagnostic Test Results , Sarcoidosis - Other diagnostic Procedure , Other disease, Other disease - Signs and symptoms, Other disease - Diagnostic Test Results , Other disease - Other Diagnostic Test Results , Other disease - Other Diagnostic Test Results , Other disease - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Laboratory Reference Ranges, Use of Human Samples by GSK, Investigator's Signature (Report Final and Annex Report 2 Final)

- 03/11/20 - 1 modulo, 8 itemgroups, 31 elementi, 1 linguaggio
Itemgroups: Administrative, Laboratory Reference Ranges, Laboratory Reference Ranges - Haematology, Laboratory Reference Ranges - Biochemistry, Laboratory Reference Ranges - Hepatic Function, Laboratory Reference Ranges - Renal Function , Use of human samples by GSK, Investigator's Signature
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Other relevant information, Investigator signature (Report Final and Annex Report 2 Final)

- 03/11/20 - 1 modulo, 3 itemgroups, 7 elementi, 1 linguaggio
Itemgroups: Administrative, Other relevant information (including evolution), Investigator Signature
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - (Glomerulo)Nephritis; Inflammatory Skin Diseases; Autoimmune Myocarditis (Report Final and Annex Report 2 Final)

- 03/11/20 - 1 modulo, 26 itemgroups, 97 elementi, 1 linguaggio
Itemgroups: Administrative, (Glomerulo)Nephritis, (Glomerulo)Nephritis - Signs and Symptoms, (Glomerulo)Nephritis - Other signs and symptoms, (Glomerulo)Nephritis - Other signs and symptoms , (Glomerulo)Nephritis - Diagnostic Test Results, (Glomerulo)Nephritis - Other Diagnostic Test Results , (Glomerulo)Nephritis - Other Diagnostic Test Results , (Glomerulo)Nephritis - Other diagnostic Procedure, Inflammatory skin diseases, Inflammatory skin diseases - Signs and symptoms, Inflammatory skin diseases - Signs and symptoms (skin lesions), Inflammatory skin diseases - Other Signs and symptoms, Inflammatory skin diseases - Other Signs and symptoms , Inflammatory skin diseases - Diagnostic Test Results, Inflammatory skin diseases - Other Diagnostic Test Results , Inflammatory skin diseases - Other Diagnostic Test Results , Inflammatory skin diseases - Other diagnostic Procedure , Autoimmune Myocarditis, Autoimmune Myocarditis - Signs and symptoms, Autoimmune Myocarditis - Other Signs and symptoms , Autoimmune Myocarditis - Other Signs and symptoms , Autoimmune Myocarditis - Diagnostic Test Results , Autoimmune Myocarditis - Other Diagnostic Test Results , Autoimmune Myocarditis - Other Diagnostic Test Results , Autoimmune Myocarditis - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Coeliac Disease; Antiphospholipid Syndrome; Autoimmune Haemolytic Anaemia (Report Final and Annex Report 2 Final)

- 03/11/20 - 1 modulo, 25 itemgroups, 87 elementi, 1 linguaggio
Itemgroups: Administrative, Coeliac disease, Coeliac disease - Signs and Symptoms, Coeliac disease - Other signs and symptoms, Coeliac disease - Other signs and symptoms , Coeliac disease - Diagnostic Test Results, Coeliac disease - Other Diagnostic Test Results , Coeliac disease - Other Diagnostic Test Results , Coeliac disease - Other diagnostic Procedure, Antiphospholipid Syndrome, Antiphospholipid Syndrome - Signs and symptoms (supporting the final diagnosis), Antiphospholipid Syndrome - Other Signs and symptoms, Antiphospholipid Syndrome - Other Signs and symptoms , Antiphospholipid Syndrome - Diagnostic Test Results, Antiphospholipid Syndrome - Other Diagnostic Test Results , Antiphospholipid Syndrome - Other Diagnostic Test Results , Antiphospholipid Syndrome - Other diagnostic Procedure , Autoimmune Haemolytic Anaemia, Autoimmune Haemolytic Anaemia - Signs and symptoms (supporting the final diagnosis), Autoimmune Haemolytic Anaemia - Other Signs and symptoms , Autoimmune Haemolytic Anaemia - Other Signs and symptoms , Autoimmune Haemolytic Anaemia - Diagnostic Test Results , Autoimmune Haemolytic Anaemia - Other Diagnostic Test Results , Autoimmune Haemolytic Anaemia - Other Diagnostic Test Results , Autoimmune Haemolytic Anaemia - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Autoimmune thyroid diseases; Addisons's disease; Inflammatory bowel diseases (Report Final and Annex Report 2 Final)

- 02/11/20 - 1 modulo, 25 itemgroups, 93 elementi, 1 linguaggio
Itemgroups: Administrative, Autoimmune thyroid diseases, Autoimmune thyroid diseases - Signs and Symptoms, Autoimmune thyroid diseases - Other signs and symptoms, Autoimmune thyroid diseases - Other signs and symptoms , Autoimmune thyroid diseases - Diagnostic Test Results, Autoimmune thyroid diseases - Other Diagnostic Test Results , Autoimmune thyroid diseases - Other Diagnostic Test Results , Autoimmune thyroid diseases - Other diagnostic Procedure, Addison's disease, Addison's disease - Signs and symptoms (supporting the final diagnosis), Addison's disease - Other Signs and symptoms, Addison's disease - Other Signs and symptoms , Addison's disease - Diagnostic Test Results, Addison's disease - Other Diagnostic Test Results , Addison's disease - Other Diagnostic Test Results , Addison's disease - Other diagnostic Procedure , Inflammatory bowel diseases, Inflammatory bowel diseases - Signs and symptoms (supporting the final diagnosis), Inflammatory bowel diseases - Other Signs and symptoms , Inflammatory bowel diseases - Other Signs and symptoms , Inflammatory bowel diseases - Diagnostic Test Results , Inflammatory bowel diseases - Other Diagnostic Test Results , Inflammatory bowel diseases - Other Diagnostic Test Results , Inflammatory bowel diseases - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - IMD Report - Scleroderma or Morphea; Dermatomyositis or Polymyositis; Diabetes mellitus Type I (Report Final and Annex Report 2 Final)

- 02/11/20 - 1 modulo, 25 itemgroups, 95 elementi, 1 linguaggio
Itemgroups: Administrative, Scleroderma or Morphea, Scleroderma or Morphea - Signs and Symptoms, Scleroderma or Morphea - Other signs and symptoms, Scleroderma or Morphea - Other signs and symptoms , Scleroderma or Morphea - Diagnostic Test Results, Scleroderma or Morphea - Other Diagnostic Test Results , Scleroderma or Morphea - Other Diagnostic Test Results , Scleroderma or Morphea - Other diagnostic Procedure, Dermatomyositis or Polymyositis, Dermatomyositis or Polymyositis - Signs and symptoms (supporting the final diagnosis), Dermatomyositis or Polymyositis - Other Signs and symptoms, Dermatomyositis or Polymyositis - Other Signs and symptoms , Dermatomyositis or Polymyositis - Diagnostic Test Results, Dermatomyositis or Polymyositis - Other Diagnostic Test Results , Dermatomyositis or Polymyositis - Other Diagnostic Test Results , Dermatomyositis or Polymyositis - Other diagnostic Procedure , Diabetes mellitus type I, Diabetes mellitus type I - Signs and symptoms (supporting the final diagnosis), Diabetes mellitus type I - Other Signs and symptoms , Diabetes mellitus type I - Other Signs and symptoms , Diabetes mellitus type I - Diagnostic Test Results , Diabetes mellitus type I - Other Diagnostic Test Results , Diabetes mellitus type I - Other Diagnostic Test Results , Diabetes mellitus type I - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Immune Mediated Disease Report; General Medical History; Relevant Risk Factors; Neurological Events; Myasthenia Gravis; Uveitis (Report Final and Annex Report 2 Final)

- 02/11/20 - 1 modulo, 31 itemgroups, 114 elementi, 1 linguaggio
Itemgroups: Administrative, IMD Report, General Medical History, General Medical History , Relevant risk factors, Neurological Events, Neurological Events - Signs and Symptoms, Neurological Events - Signs and Symptoms - Seizures, Neurological Events - Signs and Symptoms, Neurological Events - Other signs and symptoms, Neurological Events - Other signs and symptoms , Neurological Events - Diagnostic Test Results, Neurological Events - Other Diagnostic Test Results , Neurological Events - Other Diagnostic Test Results , Neurological Events - Other diagnostic Procedure, Myasthenia Gravis, Myasthenia Gravis - Signs and symptoms (supporting the final diagnosis), Myasthenia Gravis - Other Signs and symptoms, Myasthenia Gravis - Other Signs and symptoms , Myasthenia Gravis - Diagnostic Test Results, Myasthenia Gravis - Other Diagnostic Test Results , Myasthenia Gravis - Other Diagnostic Test Results , Myasthenia Gravis - Other diagnostic Procedure , Uveitis, Uveitis - Signs and symptoms (supporting the final diagnosis), Uveitis - Other Signs and symptoms , Uveitis - Other Signs and symptoms , Uveitis - Diagnostic Test Results , Uveitis - Other Diagnostic Test Results , Uveitis - Other Diagnostic Test Results , Uveitis - Other diagnostic Procedure
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Clinical activity of recMAGE-A3 + AS15 in patients with metastatic cutaneous melanoma NCT00942162 - Laboratory (Report Final and Annex Report 2 Final)

- 02/11/20 - 1 modulo, 18 itemgroups, 95 elementi, 1 linguaggio
Itemgroups: Administrative, MAGE-A3 Expression Test: Screening, MAGE-A3 Expression Test: Screening - Result, MAGE-A3 Expression Test: Screening - Result , Laboratory Responsible Signature (MAGE-A3 Expression Test: Screening), MAGE-A3 Expression Test: Screening (Re-Test), MAGE-A3 Expression Test: Screening (Re-Test) - Result , MAGE-A3 Expression Test: Screening (Re-Test) - Result, Laboratory Responsible Signature (MAGE-A3 Expression Test: Screening (Re-Test)) , Gene Profiling: Screening, Gene Profiling: Screening , Laboratory Responsible Signature (Gene Profiling: Screening), MAGE-A3 Expression Test: Recurrence, MAGE-A3 Expression Test: Recurrence - Result, MAGE-A3 Expression Test: Recurrence - Result, Gene Profiling: Recurrence, Gene Profiling: Recurrence, Laboratory Responsible Signature (Gene Profiling: Recurrence)
Study ID: 111476 Clinical Study ID: 111476 Study Title: An open, single-arm trial to assess the clinical activity of recMAGE-A3 + AS15 in patients with unresectable MAGE-A3-positive metastatic cutaneous melanoma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00942162 Sponsor: GlaxoSmithKline Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Antigen-Specific Cancer Immunotherapeutic Study Indication: Melanoma

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial